M

MedPacto Inc
KOSDAQ:235980

Watchlist Manager
MedPacto Inc
KOSDAQ:235980
Watchlist
Price: 6 880 KRW -2.27% Market Closed
Market Cap: 235.8B KRW

Net Margin
MedPacto Inc

-590.1%
Current
-371%
Average
-6.4%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-590.1%
=
Net Income
-14.6B
/
Revenue
2.5B

Net Margin Across Competitors

No Stocks Found

MedPacto Inc
Glance View

Market Cap
235.8B KRW
Industry
Biotechnology

MedPacto, Inc. researches and develops anti-cancer drugs. The company is headquartered in Seoul, Seoul. The company went IPO on 2019-12-19. The firm researches and develops anticancer drugs and diagnostic kits including vactosertib, MA-B2 and others. The products are used as the treatment of multiple myeloma, lung cancer, stomach cancer, colon cancer, blood cancer, triple negative breast cancer and pancreatic cancer, among others.

Intrinsic Value
450.81 KRW
Overvaluation 93%
Intrinsic Value
Price
M
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-590.1%
=
Net Income
-14.6B
/
Revenue
2.5B
What is the Net Margin of MedPacto Inc?

Based on MedPacto Inc's most recent financial statements, the company has Net Margin of -590.1%.

Back to Top